NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only


NSABP Foundation, Inc.



General NSABP Information
  Financial Conflicts of
     Interest Policy
  Coalition Comment:
     Reconfiguration
  IOM Report Group Comment
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on STAR
  Employment

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-43
  Protocol B-47
  Protocol B-51

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  Protocol P-5
  BreastCancerPrevention.com

Scientific Publications

Related Web Sites



Medical Search Engines



To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview


Protocol B-29
A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 PA LAR) to Tamoxifen Alone or Tamoxifen and Chemotherapy in Patients with Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer

Specific Aims
The primary aim of this study is to determine if the addition of octreotide (SMS 201-995 pa LAR) to tamoxifen alone or to tamoxifen in combination with chemotherapy prolongs disease-free survival (DFS) in women with axillary node-negative, estrogen-receptor-(ER)-positive breast cancer. Secondary aims include determining if the addition of octreotide prolongs survival, and if the rates of endometrial cancer and opposite breast cancer are altered by the concomitant administration of octreotide and tamoxifen. An additional secondary aim of this study is to determine accurate rates of several adverse events that have been reported in patients taking octreotide.